ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases in North America. Its main marketed products include NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 used to treat symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. The company also has a pipeline of investigational drugs, such as remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis (Phase 2), ACP-211 for major depressive disorder (Phase 2), ACP-711 for essential tremor (Phase 1), ACP-271 for tardive dyskinesia and Huntington's disease (Phase 1), and ACP-2591 for Rett syndrome and fragile X syndrome (Phase 1). Additionally, it has a discovery program for SYNGAP1 syndrome using antisense oligonucleotides.

ACADIA Pharmaceuticals Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ACAD. The trading currency is the US Dollar (USD), as the company is headquartered in the United States and its shares are traded on a US exchange.

ACADIA Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. This means the company is involved in using biological processes and living organisms to develop drugs and therapies, particularly for neurological and rare diseases.

ACADIA Pharmaceuticals Inc. is headquartered in the United States and primarily serves the North American market. The company focuses on the development and commercialization of medicines for neurological and rare diseases in North America, as indicated in its business description.

ACADIA Pharmaceuticals has entered into key licensing and collaboration agreements to expand its pipeline. It has a license agreement with Neuren Pharmaceuticals Limited for trofinetide, which is used in DAYBUE for Rett syndrome and other indications. Additionally, it has a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome. These partnerships help ACADIA access innovative technologies and broaden its therapeutic reach.